Citations

Showing 10 of 108104 citations.

Comparison of Clinical Laboratory Assays for Measuring Serum Infliximab and Antibodies to Infliximab
Lázár‐Molnár, Eszter , Snyder, Melissa R. , Delgado, Julio C. , Willrich, Maria Alice V.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 6 | Pages: 893-903

10.1373/jalm.2017.024869 | PMID 33636834 Get It

Abstract Background Infliximab (IFX) is a chimeric monoclonal antibody targeting tumor necrosis factor-α, used for the management of autoimmune and inflammatory diseases. Immunogenicity to this protein drug may lead to therapeutic failure. Laboratory testing for serum IFX and antidrug antibodies (ADAs) is available for the evaluation of clinical nonresponsiveness. The purpose of this study was to compare the performance of testing methodologies used by 2 clinical reference laboratories for the quantification of IFX and detection of ADAs. Methods Deidentified serum samples submitted for clinical testing were selected (n = 120) and tested at both sites. A trypsin-based LC-MS/MS assay for IFX and a bridging electrochemiluminescent immunoassay (ECLIA) for ADAs (Mayo Clinic) and a functional cell-based reporter gene assay (RGA) to measure both bioactive drug concentrations and neutralizing ADAs (ARUP Laboratories) were compared. Results In all, 105 samples had measurable concentrations of IFX by both methods and yielded a correlation coefficient (r) = 0.917, slope = 1.028, and intercept = −0.377. One outlier measured <1.0 μg/mL by LC-MS/MS and 37 μg/mL by RGA, which was confirmed to be attributed to the presence of adalimumab. Regarding detection of ADAs, 81 of 120 samples were negative by ECLIA and RGA, whereas 30 of 120 were positive by both methods, resulting in an overall 92.5% agreement. Conclusion Although there are substantial methodological differences in the assays used for detecting IFX and ADAs, results show significant concordance between the clinically validated methodologies performed in different laboratories.
Multicenter Laboratory Comparison of Iohexol Measurement
Schwartz, George J. , Wang, Hongyue , Erway, Brian, Seegmiller, Jesse C. , Bäck, Sten-Erik, Miller, W. Greg , Eckfeldt, John H., Nordin, Gunnar , Lieske, John C.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 5 | Pages: 711-724

10.1373/jalm.2017.024240 | PMID 31276084 Get It

Abstract Background Iohexol is used for measurement of kidney glomerular filtration rate (GFR). Until recently, there have not been available proficiency standards to assist in calibrating a laboratory's results. In view of a shift in calibration at the University of Rochester Medical Center (URMC) laboratory, serving as Central Biochemistry Laboratory for the CKiD study, we performed a multicentered laboratory comparison. Methods Two batches of 30 fortified sera and patient samples from serum or heparinized plasma were sent for duplicate analysis to URMC, University of Minnesota (UMN), Mayo Clinic, and University of Lund. Five proficiency testing materials from Equalis AB were also provided. Iohexol calibration was performed using dilutions of OmnipaqueTM 300 and concentrations measured by HPLC or LC-MS/MS (Mayo). Results The 2 batches sent to UMN and University of Lund agreed well. URMC calibration was 11%–13% lower, and Mayo was 4%–8% lower for fortified samples. URMC corrected calibration was 3%–8% higher for these samples. When measured values were adjusted for the results of the Equalis samples, all laboratories agreed within 1%–2% on all iohexol concentrations. Conclusions For 12 URMC calibrator lots from November 2006 to March 2016, the factor quantifying the underestimation of measured to true iohexol concentration was 0.89. If each concentration was divided by 0.89, the calculated GFRs would be reduced by 10%–11%. GFR results for CKiD were adjusted for this shift in calibration. Regular examination of iohexol proficiency testing materials, free exchange of samples among laboratories, and standardized dilution of the stock iohexol for calibration would help to bring more universal agreement to this assay.
Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients
Jannetto, Paul J. , Langman, Loralie J.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 4 | Pages: 471-472

10.1373/jalm.2017.025304 | PMID 33636905 Get It

Interference Testing and Isobaric Compounds: Is Your Mass Spectrometry-based Assay as Good as You Think It Is?
Danso, Darlington, Langman, Loralie J., Jannetto, Paul J.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 4 | Pages: 666-668

10.1373/jalm.2017.024745 | PMID 33636904 Get It

Opioids: Clinical Practice, Monitoring, and Medicolegal Considerations
Eldrige, Jason S. , Rho, Richard H., Martin, Joanne L., Murphy, Joshua B., Hooten, W. Michael

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 4 | Pages: 573-586

10.1373/jalm.2017.024026 | PMID 33636882 Get It

Abstract Background In the past decade, opioid use in the general population of the US has increased dramatically. Concomitantly, opioid-related morbidity and mortality have also risen steeply. The causes of opioid over-prescribing are multifactorial, with pressure from medical agencies, patients, aggressive patient-directed marketing, and use of patient surveys as an evaluation tool to unduly influence medical providers' decision-making. Providers also have significant concerns regarding scrutiny from their medical board and exposure to medicolegal liability. Content To provide the basis for best practice recommendations, several aspects of modern opioid prescribing practice require review. The practicing clinician should be aware of: (a) the pervasiveness of current opioid prescribing within the US; (b) the availability and applicability of clinical tools used to assess patient risk; (c) the new guidelines designed to facilitate appropriate and safe medical use of opioids; (d) the incorporation of clinical tools and best documentation practices to reduce medicolegal exposure. Summary On completion of this review, the reader should be able to recognize the magnitude of the problem of opioid over-prescribing in the US and identify several patient risk factors for opioid misuse, abuse, and/or diversion. Specifically, better familiarity with the recently published CDC guidelines for opioid prescribing will help ensure the adoption of best-use practices that maximize therapeutic efficacy while attenuating the possibility of harm to patients. A thorough review of the legal principles and risk-mitigation strategies relevant to opioid prescribing will also lessen the clinician's exposure to medicolegal liability.
Standardization of Urine Albumin Measurements: Status and Performance Goals
Miller, W. Greg , Seegmiller, Jesse C. , Narva, Andrew S., Bachmann, Lorin M, Lieske, John C.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 3 | Pages: 423-429

10.1373/jalm.2017.023614 | PMID 33636850 Get It

Abstract Background Urine albumin is a key laboratory test used for classification, assessment of risk, and monitoring treatment of patients with chronic kidney disease. Urine albumin measurement results are not standardized among different measurement procedures. Consequently, clinical guidelines using fixed decision values for urine albumin cannot be applied consistently. Content Isotope dilution mass spectrometry reference measurement procedures and certified reference materials are being developed to enable standardization of immunoassay measurement procedures for urine albumin. A previous report determined calibration bias was the major error source for differences in results among different measurement procedures for urine albumin. Performance goals for between-day precision, ≤6% CV above 15 mg/L, and for specimen-specific effects, ≤6% CV, were established on the basis of the performance capability of current measurement procedures. The biological variation model was used to estimate a total allowable error of ≤24%–30% and from that the goal for bias of ≤7%–13%. Summary A reference system of higher-order certified reference materials and reference measurement procedures is being developed to enable standardization of urine albumin measurement results. Goals have been established for total allowable error, specimen-specific effects, imprecision, and bias to facilitate efforts to standardize urine albumin measurement results.
Biomarkers for Early Detection of Acute Kidney Injury
Rizvi, Mahrukh, Rizvi, Mahrukh S, Kashani, Kianoush

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 3 | Pages: 386-399

10.1373/jalm.2017.023325 | PMID 33636842 Get It

AbstractBackgroundAcute kidney injury (AKI) is common in hospitalized patients and is associated with increased morbidity, mortality, and cost. Currently, AKI is diagnosed after symptoms manifest; available diagnostic tests (e.g., serum creatinine, urine microscopy, urine output) have limited ability to identify subclinical AKI. Because of the lack of treatment strategies, AKI typically is managed with supportive measures. However, strategies exist that may prevent renal insults in critically ill patients; therefore, early recognition of AKI is crucial for minimizing damage propagation.ContentExperimental and clinical studies have identified biomarkers that may facilitate earlier recognition of AKI or even identify patients at risk of AKI. Such biomarkers might aid in earlier implementation of preventive strategies to slow disease progression and potentially improve outcomes. This review describes some of the most promising novel biomarkers of AKI, including neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), interleukin 18 (lL-18), liver-type fatty-acid-binding protein (L-FABP), insulin-like-growth-factor-binding protein 7 (IGFBP7), and tissue inhibitor of metalloproteinase 2 (TIMP-2).SummaryWe discuss biomarker test characteristics, their strengths and weaknesses, and future directions of their clinical implementation.
Therapeutic Monoclonal Antibodies in the Clinical Laboratory
Willrich, Maria Alice V. , Willrich, Maria Alice Vieira

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 3 | Pages: 454-457

10.1373/jalm.2016.022160 | PMID 33636855 Get It

Transforming Laboratory Utilization Review into Laboratory Stewardship: Guidelines by the PLUGS National Committee for Laboratory Stewardship
Dickerson, Jane A. , Fletcher, Andrew H, Procop, Gary W. , Keren, David F. , Singh, Ila , García, Joaquín J. , Carpenter, Robert B., Miles, Joe, Jackson, Brian R. , Astion, Michael L.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 2 | Pages: 259-268

10.1373/jalm.2017.023606 | PMID 32630981 Get It

Abstract Appropriate utilization of clinical laboratory services is important for patient care and requires institutional stewardship. Clinical laboratory stewardship programs are dedicated to improving the ordering, retrieval, and interpretation of appropriate laboratory tests. In addition, these programs focus on developing, maintaining, and improving systems to provide proper financial coverage for medically necessary testing. Overall, clinical laboratory stewardship programs help clinicians improve the quality of patient care while reducing costs to patients, hospitals, and health systems. This document, which was created by a new multiinstitutional committee interested in promoting and formalizing laboratory stewardship, summarizes core elements of successful hospital-based clinical laboratory stewardship programs. The core elements will also be helpful for independent commercial clinical laboratories.
Cyanide-Nitroprusside Colorimetric Assay: A Rapid Colorimetric Screen for Urinary Cystine
Brady, Clayton , Giesen, Callen D., Voskoboev, Nikolay, Chirackal, Robin S., Gavrilov, Dimitar K. , Flanagan, Ryan M, Brady, Clayton T , Lieske, John C.

Mayo Clinic

The Journal of Applied Laboratory Medicine | July 23, 2018 | Volume: 2 | Issue: 1 | Pages: 55-64

10.1373/jalm.2016.022582 | PMID 33636959 Get It

Abstract Background Cystinuria is an autosomal recessive disorder resulting in poor proximal tubule reabsorption of cystine in the nephron, increasing the risk of cystine stone formation. A fast, inexpensive assay to screen for urinary cystine is needed because cystine stones are difficult to noninvasively differentiate from more common calcium-containing ones. Tandem mass spectrometry (MS/MS) is sensitive and specific but is labor-intensive and costly. Alternatively, a colorimetric assay is fast and cost-effective; however, creatinine interference is an issue. Methods A published cyanide-nitroprusside colorimetric assay was modified for a high-throughput microplate format. Creatinine interference was reduced using 0.1 mol/L PBS and a standard reaction time of 60 s and was further corrected using a formula derived from the slope of multiple creatinine standard curves. Results The limit of blank was determined to be 2.6 mg/L, the limit of detection 11.9 mg/L, and the limit of quantitation 15.3 mg/L. The analytic measurement range was established as 15.3–100 mg/L cystine. Intraassay and interassay CV was calculated to be 9.6% and 8.0%, respectively, for a high-level cystine concentration (83.6 mg/L). Low-level cystine (36.4 mg/L) intraassay and interassay CV was determined to be 18.1% and 17.6%, respectively. Passing–Bablok regression analysis of colorimetric vs LC-MS/MS results revealed a slope of 1.10 and y intercept of −7.14 mg/L, with an overall bias of 2% by Bland–Altman plot analysis. Conclusions We analytically validated a rapid colorimetric assay suitable to quantify urinary cystine. The effect of thiol drugs on this assay remains to be determined.